Back to Search
Start Over
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
- Source :
- Cancer. 122:868-874
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- BACKGROUND Dasatinib exhibited activity in preclinical models of sarcoma. The Sarcoma Alliance for Research through Collaboration (SARC) conducted a multicenter, phase 2 trial of dasatinib in patients with advanced sarcoma. METHODS Patients received dasatinib twice daily. The primary objective was to estimate the clinical benefit rate (CBR) (complete response or partial response within 6 months or stable disease duration of ≥6 months) with a target of ≥25%. Patients were enrolled into 1 of 7 different cohorts and assessed by imaging every 8 weeks using Choi criteria tumor response and a Bayesian hierarchical design. For each subtype, enrollment was stopped after a minimum of 9 patients were treated if there was a
- Subjects :
- 0301 basic medicine
Leiomyosarcoma
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
Cancer
medicine.disease
Undifferentiated Pleomorphic Sarcoma
Surgery
Dasatinib
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Medicine
Sarcoma
business
Rhabdomyosarcoma
Adverse effect
medicine.drug
Subjects
Details
- ISSN :
- 0008543X
- Volume :
- 122
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi...........3f3a5a0fa449c9a8e91ae664554d9c16